{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dryvax+vaccine",
    "query": {
      "intervention": "Dryvax vaccine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 43,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dryvax+vaccine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T07:04:53.259Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00857493",
      "title": "A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [
        {
          "name": "IMVAMUNE",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bavarian Nordic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "56 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "56 Years to 80 Years"
      },
      "enrollment_count": 120,
      "start_date": "2009-06",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2019-01-10",
      "last_synced_at": "2026-09-24T07:04:53.259Z",
      "location_count": 4,
      "location_summary": "Orlando, Florida • Iowa City, Iowa • Lexington, Kentucky + 1 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00857493"
    },
    {
      "nct_id": "NCT01668537",
      "title": "A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [
        {
          "name": "LF formulation of IMVAMUNE®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FD formulation of IMVAMUNE®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bavarian Nordic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 651,
      "start_date": "2013-03",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2020-10-12",
      "last_synced_at": "2026-09-24T07:04:53.259Z",
      "location_count": 3,
      "location_summary": "South Miami, Florida • Lenexa, Kansas • Lexington, Kentucky",
      "locations": [
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01668537"
    },
    {
      "nct_id": "NCT00133575",
      "title": "ACAM 3000 MVA at Harvard Medical School",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [
        {
          "name": "MVA Smallpox Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Live vaccinia virus vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "38 Years",
        "sex": "ALL",
        "summary": "18 Years to 38 Years"
      },
      "enrollment_count": 72,
      "start_date": "2005-10",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2015-01-05",
      "last_synced_at": "2026-09-24T07:04:53.259Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00133575"
    },
    {
      "nct_id": "NCT00189904",
      "title": "Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "IMVAMUNE (MVA-BN)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bavarian Nordic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 151,
      "start_date": "2005-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-09-28",
      "last_synced_at": "2026-09-24T07:04:53.259Z",
      "location_count": 5,
      "location_summary": "Indianapolis, Indiana • Lexington, Kentucky • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00189904"
    },
    {
      "nct_id": "NCT00079820",
      "title": "Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [
        {
          "name": "ACAM3000 MVA Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "31 Years",
        "sex": "ALL",
        "summary": "18 Years to 31 Years"
      },
      "enrollment_count": 110,
      "start_date": "2004-04",
      "completion_date": "2006-10",
      "has_results": false,
      "last_update_posted_date": "2014-01-13",
      "last_synced_at": "2026-09-24T07:04:53.259Z",
      "location_count": 2,
      "location_summary": "Lenexa, Kansas • Lexington, Kentucky",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00079820"
    },
    {
      "nct_id": "NCT01395082",
      "title": "ACAM2000® Myopericarditis Registry",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myocarditis",
        "Pericarditis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2011-04",
      "completion_date": "2019-02-04",
      "has_results": false,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-09-24T07:04:53.259Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01395082"
    },
    {
      "nct_id": "NCT00053495",
      "title": "Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [
        {
          "name": "Vaccinia virus: ACAM2000 smallpox vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "vaccinia virus (calf lymph): Dryvax",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "18 Years to 29 Years"
      },
      "enrollment_count": 353,
      "start_date": "2003-01",
      "completion_date": "2003-11",
      "has_results": true,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-09-24T07:04:53.259Z",
      "location_count": 4,
      "location_summary": "Orlando, Florida • Lenexa, Kansas • Springfield, Missouri + 1 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "Pawtucket",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00053495"
    },
    {
      "nct_id": "NCT01158157",
      "title": "VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Smallpox Vaccine Adverse Reaction"
      ],
      "interventions": [
        {
          "name": "ACAM2000",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 25,
      "start_date": "2010-09-13",
      "completion_date": "2012-02-14",
      "has_results": true,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-09-24T07:04:53.259Z",
      "location_count": 1,
      "location_summary": "Altamonte Springs, Florida",
      "locations": [
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01158157"
    },
    {
      "nct_id": "NCT00068198",
      "title": "Human Immune Responses Smallpox",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [
        {
          "name": "Dryvax",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 45,
      "start_date": null,
      "completion_date": "2004-11",
      "has_results": false,
      "last_update_posted_date": "2010-08-27",
      "last_synced_at": "2026-09-24T07:04:53.259Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00068198"
    },
    {
      "nct_id": "NCT00000767",
      "title": "A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "TBC-3B Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Smallpox Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 18,
      "start_date": null,
      "completion_date": "1996-07",
      "has_results": false,
      "last_update_posted_date": "2021-10-28",
      "last_synced_at": "2026-09-24T07:04:53.259Z",
      "location_count": 5,
      "location_summary": "St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000767"
    }
  ]
}